Insulin therapy in type 1 diabetes

Insulin delivery systems, initiation of insulin therapy and insulin regimens
Insulin continues to play a key role in glycemic control in type 1 diabetes. Administration methods include syringe, pen or pump (continuous subcutaneous insulin infusion [CSII] ). Inhaled insulin has been approved for use in Canada, but is not yet commercially available. Client education should include comprehensive information on caring for and using insulin; prevention, recognition and treatment of hypoglycemia; sick-day management; adjustments for food intake (e.g., carbohydrate counting) and physical activity; and self-monitoring of blood glucose (SMBG).
Insulin regimens should be targeted to the individual's treatment goals, lifestyle, diet, age, general health, motivation, hypoglycemia awareness status and ability to self-manage. Social and financial aspects should also be considered (e.g., individuals living alone or those requiring caregiver support).
Multiple daily insulin injections (prandial [bolus] and basal insulin) or CSII as part of an intensive diabetes management regimen is the treatment of choice [Grade A, Level 1A]. Basal refers to insulin produced between meals and during overnight fasting, while prandial insulin is that administered above basal at mealtime.
Administering multiple daily injections is the preferred method to attempt to duplicate normal pancreatic insulin secretion. Conventional (fixed-dose) insulin regimens are no longer in favour. Based on the Diabetes Control and Complications Trial, intensive treatment of type 1 diabetes significantly delays the onset and slows the progression of microvascular and macrovascular complications. The most successful protocols are the basal-bolus (basal-prandial) regimens or CSII. For the basalbolus regimen, basal insulin is provided by an intermediate-acting insulin or a long-acting insulin analogue once or twice daily. Prandial insulin is provided by a short-acting insulin or a rapidacting insulin analogue given at each meal.
Regular insulin should be administered 30 to 45 minutes prior to a meal, whereas insulin aspart and insulin lispro should be administered 0 to 15 minutes before meals and up to 15 minutes after a meal. However, preprandial injections achieve better postprandial control and possibly better overall glycemic control.
Rapid-acting insulin analogues (aspart or lispro), combined with adequate basal insulin, should be considered over regular insulin to improve A1C while minimizing hypoglycemia [Grade B, Level 2] and to achieve postprandial glucose targets [Grade B, Level 2] . They should be used when CSII is used in adults [Grade B, Level 2] . Their use improves postprandial glycemic control and reduces hypoglycemia.
A long-acting insulin analogue (detemir, glargine) (with regular insulin or rapid-acting insulin analogues for meals) may be considered as an alternative to NPH as the basal insulin [Grade B, Level 2], for lower FPG levels and to reduce the risk of hypoglycemia [Grade B, Level 2 for detemir; Grade C, Level 3, for glargine], including nocturnal hypoglycemia [Grade B, Level 2 for detemir; Grade D, Consensus, for glargine].
Hypoglycemia
Insulin-induced hypoglycemia is a major obstacle for individuals trying to achieve glycemic targets. Hypoglycemia can be severe and result in confusion, coma or seizure. Those who deviate from appropriate self-medication behaviours (e.g., eating less food, taking more insulin, being more active) account for 85% of hypoglycemic episodes.
All individuals with type 1 diabetes should be counselled All individuals with type 1 diabetes should be counselled about the risk and prevention of insulin-induced hypoglycemia • For patients on long-standing fixed-dose regimens, pharmacists and prescribers should discuss the benefits of switching to multiple daily injections tailored to the individual's insulin requirements.
• Educate patients about factors that can predispose them to hypoglycemia, such as lack of education about hypoglycemia, alcohol consumption without adequate carbohydrate ingestion, exercise and missed or delayed meals.
• Keep track of glucagon prescriptions in persons using insulin. Glucagon has a relatively short shelf-life and needs to be re-dispensed often; excessive use may merit a suggestion to contact the physician about excessive hypoglycemic episodes. 
Practice Tips
Hypoglycemia unawareness and nocturnal hypoglycemia
Hypoglycemia unawareness occurs when the threshold for the development of autonomic warning symptoms is close to or lower than the threshold for the neuroglycopenic symptoms, so the first signs of hypoglycemia will often be confusion or loss of consciousness. Hypoglycemia unawareness may be reversible. Strict avoidance of hypoglycemia for a period of 2 days to 3 months has been associated with improved recognition of severe hypoglycemia, in the counterregulatory hormone responses, or both.
The following strategies may help individuals with hypoglycemia unawareness reduce the risk and regain awareness: • Increased self-monitoring of blood glucose frequency, including periodic assessment during sleeping hours [Grade D, Consensus] • Less stringent glycemic targets with avoidance of hypoglycemia [Grade C, Level 3] • A psychobehavioural intervention program (e.g., blood glucose awareness training), if available [Grade B, Level 2] Asymptomatic nocturnal hypoglycemia is common and can occur when the sympathoadrenal response to hypoglycemia is reduced during sleep. ■ (See also Hypo-and hyperglycemic emergencies in adults, p. S26.)
